Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression

Young E. Whang, Xinyi Wu, Hiroyoshi Suzuki, Robert E. Reiter, Chris Tran, Robert L. Vessella, Jonathan W. Said, William B. Isaacs, Charles L. Sawyers

Research output: Contribution to journalArticlepeer-review


The recently identified PTEN/MMAC1 gene is a candidate tumor suppressor implicated in multiple tumor types based on mutations or homozygous deletions of the gene in certain human cancers. No studies of PTEN/MMAC1 mRNA or protein expression in cancer cells have been reported, primarily because of significant numbers of normal cells contaminating most tumor samples and because of the lack of antibody reagents. We examined PTEN/MMAC1 in advanced prostate cancer for gene mutations or abnormalities in expression by using a series of recently derived xenografts free of normal human cells and a PTEN/MMAC1-specific antibody. Only 1 of 10 tumors contained a homozygous deletion of PTEN/MMAC1, and no mutations were detected in the entire coding region of the remaining nine xenografts. However, five of these showed reduced or absent PTEN/MMAC1 expression by Northern analysis and reverse transcription-PCR of mRNA. PTEN/MMAC1 mRNA expression was restored in nonexpressing prostate cancer cells by in vitro treatment with the demethylating agent 5-azadeoxycytidine. Alterations in PTEN/MMAC1 expression were confirmed at the protein level by immunoblot analysis, and immunohistochemical studies show that the endogenous wild-type PTEN/MMAC1 protein is localized exclusively in the cytoplasm. These results demonstrate that loss of PTEN/MMAC1 expression occurs frequently in advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)5246-5250
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number9
StatePublished - Apr 28 1998

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression'. Together they form a unique fingerprint.

Cite this